TY - JOUR
T1 - Diagnosis and management of breast lymphoma: A single-institution retrospective analysis
AU - Orlandi, Armando
AU - Sanchez, Alejandro Martin
AU - Calegari, Maria Alessandra
AU - D'Archi, Sabatino
AU - Santoro, Agostino Antonio
AU - Di Leone, Alba
AU - Mule', Antonino
AU - Arena, Vincenzo
AU - Masetti, Riccardo
AU - Barone, Carlo Antonio
AU - Franceschini, Gianluca
PY - 2018
Y1 - 2018
N2 - Background: Breast lymphoma (BL) is a rare entity. Although mimicking clinical presentation and radiological features of epithelial breast malignancies, prognosis and treatment management are different. Here we report our single institution experience in such population.Methods: The database of our pathology institute was retrospectively searched for breast neoplasms coded as lymphoma from January 2000 to January 2017. The assessed data were: gender, age at diagnosis, laterality, stage (primary or secondary), histopathological diagnosis and grading (high vs. low) treatment, recurrence and survival status. Progression-free survival (PFS), overall survival (OS) and 5-year recurrence rate were estimated. An exploratory analysis comparing survival (PFS, OS and 5-year recurrence rate) between high- and low-grade histotypes and primary and secondary stages was performed.Results: Fifteen patients were included in the analysis. All patients were affected by B-cell type lymphomas; the most frequent subtype was diffuse large B-cell lymphoma (DLBCL). Patients affected by high-grade lymphomas were treated with polychemotherapy followed in about half of cases by consolidative ipsilateral breast radiotherapy. Patients affected by low-grade lymphomas were treated with local treatment only (surgical resection +/- radiotherapy). No patient received radical surgery or axillary dissection. At a median follow up of 9 years, four patients had relapsed (all affected by high-grade lymphomas) with central nervous system (CNS) involved in half cases. Both median PFS and OS were not reached, but a slight trend toward a better survival was noticed in favor of primary breast lymphoma (PBL), while a clearer survival benefit was observed in the low-grade cohort. The estimated 5-year survival rate was 77% within the whole population, 78% vs. 66% for primary vs. secondary and 100% vs. 66% for low-grade vs. high-grade BL.Conclusions: Our data concerning clinical and pathological features are consistent with those previously reported. Management of disease was based on histology. Although being a rare disease it is mandatory to take it into account for differential diagnosis since treatment and prognosis differs widely from primary breast malignancies.
AB - Background: Breast lymphoma (BL) is a rare entity. Although mimicking clinical presentation and radiological features of epithelial breast malignancies, prognosis and treatment management are different. Here we report our single institution experience in such population.Methods: The database of our pathology institute was retrospectively searched for breast neoplasms coded as lymphoma from January 2000 to January 2017. The assessed data were: gender, age at diagnosis, laterality, stage (primary or secondary), histopathological diagnosis and grading (high vs. low) treatment, recurrence and survival status. Progression-free survival (PFS), overall survival (OS) and 5-year recurrence rate were estimated. An exploratory analysis comparing survival (PFS, OS and 5-year recurrence rate) between high- and low-grade histotypes and primary and secondary stages was performed.Results: Fifteen patients were included in the analysis. All patients were affected by B-cell type lymphomas; the most frequent subtype was diffuse large B-cell lymphoma (DLBCL). Patients affected by high-grade lymphomas were treated with polychemotherapy followed in about half of cases by consolidative ipsilateral breast radiotherapy. Patients affected by low-grade lymphomas were treated with local treatment only (surgical resection +/- radiotherapy). No patient received radical surgery or axillary dissection. At a median follow up of 9 years, four patients had relapsed (all affected by high-grade lymphomas) with central nervous system (CNS) involved in half cases. Both median PFS and OS were not reached, but a slight trend toward a better survival was noticed in favor of primary breast lymphoma (PBL), while a clearer survival benefit was observed in the low-grade cohort. The estimated 5-year survival rate was 77% within the whole population, 78% vs. 66% for primary vs. secondary and 100% vs. 66% for low-grade vs. high-grade BL.Conclusions: Our data concerning clinical and pathological features are consistent with those previously reported. Management of disease was based on histology. Although being a rare disease it is mandatory to take it into account for differential diagnosis since treatment and prognosis differs widely from primary breast malignancies.
KW - High grade lymphoma
KW - Low grade lymphoma
KW - Primary breast lymphoma (PBL)
KW - Secondary breast lymphoma (SBL)
KW - High grade lymphoma
KW - Low grade lymphoma
KW - Primary breast lymphoma (PBL)
KW - Secondary breast lymphoma (SBL)
UR - http://hdl.handle.net/10807/143205
UR - http://tcr.amegroups.com/article/download/17996/pdf
U2 - 10.21037/tcr.2017.11.10
DO - 10.21037/tcr.2017.11.10
M3 - Article
SN - 2218-676X
VL - 7
SP - S272-S280
JO - Translational Cancer Research
JF - Translational Cancer Research
ER -